Powerful, Non-Sedating Relief

For patients tired of allergy symptoms who can’t risk drowsiness from medication

Every patient is different and can have a variety of symptoms. For itchy, watery eyes, scratchy throat, runny nose, and sneezing, Allegra provides powerful allergy relief for those patients* who can’t afford to slow down during their day.

*See Drug Facts label. Use as directed.


Unsurpassed  speed and efficacy

A 2-week, placebo-controlled, randomized study of patients with moderate to severe allergic rhinitis (n=861). The TSS was the sum of individual symptoms (sneezing; rhinorrhea; itchy nose/mouth/throat; and itchy, watery red eyes) and ranged from 0 to 16. Baseline scores were placebo 7.6; Allegra 7.7.


Among single-ingredient branded OTC oral anthistamines.

Starts working in one hour. Refers to first dose only.
aMean reduction in 8AM instantaneous TSS. Adapted from Casale TB, et al.1 Used with permission.

References: 3. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCI in the treatment of autumn seasonal allergic rhinitis. Allergy Asthma Proc. 1999;20(3):193-198.

Footnotes & References

Non-sedating relief, even at 30,000 feet

Real-world use—safe enough for pilots

Approved by the Federal Aviation Administration (FAA) for use by pilots4
  • The FAA has, under special conditions, medically qualified pilots and air traffic controllers who are using Allegra
  • According to FAA guidelines, pilots may use non-sedating antihistamines while flying after individual experience has determined that the medication is well tolerated
  • A minimum of 72 hours of ground trial is required at initiation of therapy to ensure adequate symptom control and to exclude idiosyncratic reaction§
No warnings for drowsiness while driving5,6

§US Air Force and US Army guidelines approve the use of Allegra, without a waiver, for treatment of mild seasonal allergies. Allegra also can be used, with a waiver, for the treatment of chronic or recurrent allergic rhinitis. Approvals refer to Allegra single entity.

References: 4. Federal Aviation Administration. Guide for aviation medical examiners: pharmaceuticals (therapeutic medications). https://www.faa.gov/about/office_org/ headquarters_offices/avs/offices/aam/ame/guide. Accessed August 6, 2018. 5. Weiler JM, Bloomfield JR, Woodworth GG, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa Driving Simulator. Ann Intern Med. 2000;132:354-363. 6. ALLEGRA Allergy [drug facts label]. Bridgewater, NJ:sanofi-aventis U.S. LLC.

Footnotes & References

Does not cross the blood-brain barrier (BBB)7

Does not affect histamine receptors in the brain.7

Cognitive and psychomotor results similar to baseline, even at 2X the recommended qd dose (Allegra 360 mg)

Baseline  Color indicates no displacement of radiolabeled doxepin
Allegra 360 mg  Color indicates no displacement of radiolabeled doxepin

Positron emission tomography (PET) images show radiolabeled doxepin bound to central nervous system (CNS) H1 receptors to demonstrate substances crossing the BBB. PET images shown taken at peak plasma levels at 90 minutes. Adapted from Howarth PH.7 Used with permission.

References: 7. Howarth PH. The choice of an H1-antihistamine for the 21st century. Clin Exp Allergy Rev. 2002;2:18-25.

Footnotes & References